2008
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow
Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow. Journal Of Nuclear Medicine 2008, 49: 517-523. PMID: 18344436, DOI: 10.2967/jnumed.107.048504.Peer-Reviewed Original ResearchConceptsBlood flowUptake scanPET scansControl ROIMore tumor sitesFirst-pass uptakeTumor blood flowEarly uptakeRegional blood flowNovel antiangiogenic agentsArterial blood concentrationDose-escalating protocolPET molecular imagingMeasured blood flowPerfusion scanEstimate of perfusionBlood concentrationsBolus injectionProstate cancerAntiangiogenic agentsTumor perfusionGlucose metabolismBlood flow analysisBack musclesLarge arteries
2002
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O’Reilly M, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. Journal Of Clinical Oncology 2002, 20: 3804-14. PMID: 12228200, DOI: 10.1200/jco.2002.05.102.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAngiogenesis InhibitorsApoptosisBiomarkersCD3 ComplexCollagenDose-Response Relationship, DrugEndostatinsEndotheliumFemaleFluorodeoxyglucose F18HumansIn Situ Nick-End LabelingLasersMaleMiddle AgedNeoplasmsNeovascularization, PathologicPeptide FragmentsProspective StudiesRecombinant ProteinsTomography, Emission-ComputedConceptsTumor blood flowRh-EndoTumor cell apoptosisPositron emission tomographyBlood flowEndothelial cell apoptosisCell apoptosisClinical trialsAntiangiogenic therapyEndothelial cellsWeeks of therapyStart of therapyDose-finding clinical trialsRecombinant human endostatinHuman recombinant endostatinTreatment of cancerBiologic markersAntiangiogenic treatmentBiopsy specimensAppropriate dosePET scansBiopsy analysisHuman endostatinTherapyTumor tissue
2000
9:30—9:45 First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow
Mullani N, Herbst R, Abbruzzese J, Barron B, Lamki L, Charnsangavej C, Kim E, Tran H, Jiwani A, Gould K. 9:30—9:45 First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow. Molecular Imaging And Biology 2000, 3: 153. PMID: 11150756, DOI: 10.1016/s1095-0397(00)00065-0.Peer-Reviewed Original ResearchBlood flowRegional blood flowNovel antiangiogenic agentsBlood flow valuesOne-compartment modelMeasured blood flowAbsence of perfusionBlood flow tracerPerfusion scanEstimate of perfusionBolus injectionAntiangiogenic agentsPET scansTumor perfusionMCi doseLinear regression analysisFDGTumor sitePhase IPerfusion tracerPerfusionTumorsTwo minutesScansRegression analysis